SMTL ID : 8gne.1

Crystal structure of human adenosine A2A receptor in complex with an insurmountable inverse agonist, KW-6356.

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 2.30 Å

Oligo State

monomer

Ligands

1 x JQR: ~{N}-[4-(furan-2-yl)-5-(oxan-4-ylcarbonyl)-1,3-thiazol-2-yl]-6-methyl-pyridine-3-carboxamide(Non-covalent)

JQR.1: 16 residues within 4Å: Chain A: A.72, I.75, A.90, V.93, L.94, F.177, E.178, M.186, W.351, L.354, H.355, N.358, T.361, H.369, M.375, I.379 10 PLIP interactions: 10 interactions with chain A Hydrophobic interactions: A:V.93, A:L.94, A:F.177, A:E.178, A:W.351, A:I.379 Hydrogen bonds: A:N.358, A:N.358 Water bridges: A:A.72 pi-Stacking: A:F.177

3 x CLR: CHOLESTEROL(Non-covalent)

CLR.2: 7 residues within 4Å: Chain A: F.191, L.352, C.359, F.360, F.363, C.364 Ligands: OLC.5 7 PLIP interactions: 7 interactions with chain A Hydrophobic interactions: A:F.191, A:L.352, A:F.360, A:F.360, A:F.360, A:F.360, A:F.363 CLR.3: 9 residues within 4Å: Chain A: L.67, F.71, A.81, A.82, G.85, F.88, I.89 Ligands: OLC.13, OLC.21 8 PLIP interactions: 8 interactions with chain A Hydrophobic interactions: A:L.67, A:F.71, A:A.81, A:F.88, A:I.89, A:I.89 Hydrogen bonds: A:A.82 Water bridges: A:Q.172 CLR.4: 8 residues within 4Å: Chain A: L.349, P.353, I.356, I.357, F.360, C.367, S.368, L.374 8 PLIP interactions: 8 interactions with chain A Hydrophobic interactions: A:L.349, A:P.353, A:I.356, A:I.356, A:I.357, A:F.360, A:F.360, A:L.374

18 x OLC: (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate(Non-covalent)(Non-functional Binders)

OLC.5: 5 residues within 4Å: Chain A: F.192, L.196, F.363 Ligands: CLR.2, OLC.12 Ligand excluded by PLIP OLC.6: 11 residues within 4Å: Chain A: G.14, V.17, Y.18, V.21, C.350, W.373, Y.376, V.380, T.384, V.388 Ligands: OLC.17 Ligand excluded by PLIP OLC.7: 8 residues within 4Å: Chain A: Y.52, V.55, A.59, F.92, G.127, K.131, W.138 Ligands: OLC.8 Ligand excluded by PLIP OLC.8: 11 residues within 4Å: Chain A: C.37, V.40, W.41, Q.47, Y.52, V.55, A.59, I.62, L.67 Ligands: OLC.7, OLC.16 Ligand excluded by PLIP OLC.9: 2 residues within 4Å: Ligands: OLC.20, OLC.21 Ligand excluded by PLIP OLC.10: 3 residues within 4Å: Chain A: V.27, T.77 Ligands: OLC.20 Ligand excluded by PLIP OLC.11: 5 residues within 4Å: Chain A: Y.188, F.192, A.193, F.362 Ligands: OLC.12 Ligand excluded by PLIP OLC.12: 6 residues within 4Å: Chain A: Y.188, F.192, V.197, F.363 Ligands: OLC.5, OLC.11 Ligand excluded by PLIP OLC.13: 5 residues within 4Å: Chain A: A.82, H.84, G.85 Ligands: CLR.3, OLC.14 Ligand excluded by PLIP OLC.14: 3 residues within 4Å: Chain A: H.84, L.146 Ligands: OLC.13 Ligand excluded by PLIP OLC.15: 1 residues within 4Å: Chain A: L.211 Ligand excluded by PLIP OLC.16: 5 residues within 4Å: Chain A: C.37, W.41 Ligands: OLC.8, OLC.21, OLC.22 Ligand excluded by PLIP OLC.17: 9 residues within 4Å: Chain A: I.25, L.28, V.387, V.388, F.391, I.392, Y.395, R.396 Ligands: OLC.6 Ligand excluded by PLIP OLC.18: 7 residues within 4Å: Chain A: I.109, Y.112, I.113, L.124, A.193, C.194, P.198 Ligand excluded by PLIP OLC.19: 7 residues within 4Å: Chain A: A.106, I.109, D.110, L.124, V.125, R.129, I.133 Ligand excluded by PLIP OLC.20: 6 residues within 4Å: Chain A: P.70, T.74, F.79 Ligands: OLC.9, OLC.10, OLC.21 Ligand excluded by PLIP OLC.21: 8 residues within 4Å: Chain A: F.71, T.74, F.79, C.80 Ligands: CLR.3, OLC.9, OLC.16, OLC.20 Ligand excluded by PLIP OLC.22: 6 residues within 4Å: Chain A: V.34, W.38, W.41, L.42, H.411 Ligands: OLC.16 Ligand excluded by PLIP

1 x PE4: 2-{2-[2-(2-{2-[2-(2-ETHOXY-ETHOXY)-ETHOXY]-ETHOXY}-ETHOXY)-ETHOXY]-ETHOXY}-ETHANOL(Non-functional Binders)

PE4.23: 6 residues within 4Å: Chain A: L.28, G.32, L.35, V.387, P.390, F.391 1 PLIP interactions: 1 interactions with chain A Hydrogen bonds: A:G.32

1 x NA: SODIUM ION(Non-functional Binders)

NA.24: 3 residues within 4Å: Chain A: D.61, S.100, N.385 2 PLIP interactions: 2 interactions with chain A Hydrogen bonds: A:D.61, A:S.100

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Ohno, Y. et al., In Vitro Pharmacological Profile of KW-6356, a Novel Adenosine A 2A Receptor Antagonist/Inverse Agonist. Mol.Pharmacol. (2023)

Release Date

2023-03-22

Peptides

Adenosine receptor A2a,Soluble cytochrome b562: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

Membrane

We predict this structure to be a membrane protein.
Show / Hide

Adenosine receptor A2a,Soluble cytochrome b562